Category Archives: Hyperbaric Studies
Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial.Related Articles
Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial.
Cytotherapy. 2013 Nov 27;
Authors: Wu Z, Cai J, Chen J, Huang L, Wu W, Luo F, Wu C, Liao L, Tan J
Abstract BACKGROUND AIMS: The use of bone marrow mononuclear cells (BM-MNCs) has achieved great outcomes in clinical practice. We aim to evaluate the efficacy and safety of autologous BM-MNC infusion and hyperbaric oxygen therapy (HOT) in type 2 diabetes mellitus. METHODS: This single-center, randomized, open-label, controlled clinical trial with a factorial design included two phases. The patients received standard medical therapy in the run-in phase; in the treatment phase, patients with glycated hemoglobin of 7.5-9.5% were randomly assigned into four groups and underwent BM-MNC infusion along with HOT (BM-MNC+HOT group), BM-MNC infusion (BM-MNC group), HOT (HOT group) and standard medical therapy (control group), respectively. The area under the curve of C-peptide was recorded as a primary end point. Our research is registered at ClinicalTrials.gov (NCT00767260). RESULTS: A total of 80 patients completed the follow-up. At 12 months after treatment, the area under the curve of C-peptide (ng/mL per 180 min) of the BM-MNC+HOT group and the BM-MNC group were significantly improved (34.0% and 43.8% from the baseline, respectively). The changes were both significant compared with that in the control group, but no remarkable change was observed in the HOT group. Treatment-related adverse events were mild, including transient abdominal pain (n = 5) and punctual hemorrhage (n = 3). CONCLUSIONS: BM-MNC infusion for type 2 diabetes mellitus improves islet function and metabolic control, with mild adverse effects. HOT does not synergize with BM-MNC infusion.
PMID: 24290656 [PubMed - as supplied by publisher]
Interleukin 10 mediates the neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice.Related Articles
Interleukin 10 mediates the neuroprotection of hyperbaric oxygen therapy against traumatic brain injury in mice.
Neuroscience. 2013 Nov 26;
Authors: Chen X, Duan XS, Xu LJ, Zhao JJ, She ZF, Chen WW, Zheng ZJ, Jiang GD
Abstract The aim of present study was to elucidate the role of Interleukin-10 (IL-10) in the neuroprotection of hyperbaric oxygen (HBO) against traumatic brain injury (TBI) in mice. The TBI in mice was induced by controlled cortical impact (CCI). HBO was given for 1 hour at 2.0 ATA in 100% O2. HBO enhanced the serumal and cerebral IL-10 protein levels in both sham-operated and TBI mice. HBO therapy after TBI reduced lesion volume, attenuated cerebral edema, improved neurological status including motor and cognitive function, inhibited apoptosis evidenced by decreased ratio of cleaved caspase 3 (C3) to pro-C3 and Bax expression and increased bcl-2 expression, and attenuated inflammation marked by reduced expression of IL-1β, IL-6, macrophage inflammatory protein-2 (MIP-2), and monocyte chemoattractant protein (MCP)-1 and activity of matrix metalloproteinase-9 (MMP9). In addition, HBO after TBI improved blood-brain barrier, and upregulated expression of tight junction proteins including zonula occludens-1 (ZO-1) and claudin-5. IL-10 deficiency aggravated TBI-induced damage in brain and abrogated the beneficial effects of HBO on neuroinflammation, apoptosis, and edema after TBI. IL-10 deficiency itself had no significant effect on brain water content and neurological status. In conclusion, IL-10 played an important role in the neuroprotection of HBO therapy against TBI in mice.
PMID: 24291771 [PubMed - as supplied by publisher]
Management of radiation proctitis.
Gastroenterol Clin North Am. 2013 Dec;42(4):913-25
Authors: Sarin A, Safar B
Abstract Radiation damage to the rectum following radiotherapy for pelvic malignancies can range from acute dose-limiting side effects to major morbidity affecting health-related quality of life. No standard guidelines exist for diagnosis and management of radiation proctitis. This article reviews the definitions, staging, and clinical features of radiation proctitis, and summarizes the modalities available for the treatment of acute and chronic radiation proctitis. Because of the paucity of well-controlled, blinded, randomized studies, it is not possible to fully assess the comparative efficacy of the different approaches to management. However, the evidence and rationale for use of the different strategies are presented.
PMID: 24280407 [PubMed - in process]
Restoring Vascular Function with Hyperbaric Oxygen Treatment: Recovery Mechanisms.
J Vasc Res. 2013 Nov 19;51(1):1-13
Authors: Drenjancevic I, Kibel A
Abstract Treatment with hyperbaric oxygen can be a beneficial adjuvant therapy in various disorders characterized by compromised tissue oxygenation and perfusion. However, the effects of hyperbaric oxygenation cannot be simply explained as a compensation of the oxygen deficit. Hyperbaric oxigenation has a much broader influence and has the ability to alter protein expression, modulate signaling pathways and affect vascular structure and function. We discuss some of the most important uses of hyperbaric oxigenation for clinical conditions that involve abnormal vascular function. We present recent studies and insights into the mechanisms and effects of hyperbaric oxygen in the vasculature. © 2013 S. Karger AG, Basel.
PMID: 24280807 [PubMed - as supplied by publisher]
Healing under pressure: hyperbaric oxygen and myocutaneous flap repair for extreme persistent perineal sinus after proctectomy for inflammatory bowel disease.Related Articles
Healing under pressure: hyperbaric oxygen and myocutaneous flap repair for extreme persistent perineal sinus after proctectomy for inflammatory bowel disease.
Colorectal Dis. 2013 Nov 22;
Authors: Chan XH, Koh CE, Glover M, Bryson P, Travis SP, Mortensen NJ
Abstract AIM: persistent perineal sinus (PPS) following proctectomy for inflammatory bowel disease affects about 50% of patients. Up to 33% of PPS remain unhealed at 12 months and the most refractory cases are unhealed at 24 months despite best conventional therapy. Reports of hyperbaric oxygen therapy (HBOT) for chronic wounds and Crohn's perianal disease led us to explore peri-operative HBOT with rectus abdominis myocutaneous (RAM) flap repair in a highly-selected group of patients with extreme PPS who had failed all other interventions. METHOD: Patients with extreme PPS received pre-operative HBOT (up to thirty 90-minute sessions at 2.2-2.4 atmospheres, 5x/week for 5-6 weeks), before abdominoperineal PPS excision and perineal reconstruction with vertical or transverse RAM flap within 2-4 weeks of completing HBOT. Post-operative HBOT (ten further 90-minute sessions) was administered within 2 weeks where practicable. RESULTS: Between 2007 and 2011, four patients with extreme PPS underwent RAM flap repair with pre-operative HBOT, two also received post-operative HBOT. Median duration of PPS prior to HBOT was 88.5 months (23-156 months). All patients had previously failed multiple (5 to >35) surgical procedures. Complete healing occurred in all patients at median follow-up of 2.5 months (2-3 months). There were no further hospital admissions for PPS at median follow-up of 35 months (8-64 months). CONCLUSION: HBOT combined with PPS excision and perineal reconstruction with a RAM flap led to complete perineal healing in four patients with extreme PPS and appears a safe and effective extension to the therapeutic pathway for exceptionally treatment-refractory PPS. This article is protected by copyright. All rights reserved.
PMID: 24267200 [PubMed - as supplied by publisher]